Business
PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide
About this update from Pepgen Inc.
[{"type":"text","content":"BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the 2023 American Academy of Neurology (AAN) Annual Meeting, taking place on April 22-27, 2023 in Boston, Massachusetts. Oral Presentation: Title: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Myotonic Dystrophy Type 1 (DM1)Program Number: S48.001Session Topic: Therapeutics for Muscle Disease Date & Time: Thursday, April 27, 2023 at 3:30pm ETPresenter: Ashling Holland, Ph.D., Director of Preclinical Development Poster Presentation: Title: Preclinical Data Supporting the Development of an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD)Program Number: P3.002Session Topic: Neuromuscular Disease: Inherited Muscle Disorders 1 Date & Time: Sunday, April 23, at 5:30pm ET Presenter: Ashling Holland, Ph.D., Director of Preclinical Development Title: PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD): Results of a Phase 1 Study in Healthy VolunteersProgram Number: P3.004Session Topic: Neuromuscular Disease: Inherited Muscle Disorders 1 Date & Time: Sunday, April 23, at 5:30pm ETPresenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development Title: Design of a Phase 1, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of PGN-EDODM1 in Adult Participants with Myotonic Dystrophy Type 1 (DM1)Program Number: P6.004Session Topic: Neuromuscular Disease: Inherited Muscle Disorders 3 Date & Time: Monday, April 24, at 5:30pm ETPresenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development About PepGen PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to ...